Stromal cells as a part of tumor microenvironment of melanoma: Their role in cancer progression and drug resistance

Rafał Matkowski[1,2,A–F], Aleksandra Simiczyjew[3,A–F], Marcin Ziętek[1,2,A–F], Dorota Nowak[3,A–F]

[1] Department of Oncology, Faculty of Medicine, Wroclaw Medical University, Poland
[2] Lower Silesian Oncology, Pulmonology and Hematology Center, Wrocław, Poland
[3] Department of Cell Pathology, Faculty of Biotechnology, University of Wrocław, Poland

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation;
D – writing the article; E – critical revision of the article; F – final approval of the article

Abstract

Today, it is well established that the tumor microenvironment (TME), the tumor niche, along with melanoma cells, plays a crucial role in cancer dissemination and influences the effectiveness of anticancer therapies. Therefore, it may serve as a potential therapeutic target in melanoma treatment. In our research, we focused on the effects exerted by cells within the melanoma microenvironment on cancer progression and the development of therapy resistance. Specifically, we examined stromal cells accompanying melanoma cells in the tumor – cancer-associated fibroblasts (CAFs), cancer-associated keratinocytes (CAKs), and cancer-associated adipocytes (CAAs). Particular attention was given to keratinocytes, as their role in the melanoma microenvironment remains the least understood.

Key words: melanoma, drug resistance, stromal cells, microenvironment, signaling pathways

<div style="border: 1px solid blue;">

Highlights

- The melanoma tumor microenvironment (TME) plays a critical role in cancer progression, metastasis, and resistance to anticancer therapies.
- Stromal cells, including cancer-associated fibroblasts (CAFs), keratinocytes (CAKs), and adipocytes (CAAs), actively influence melanoma cell behavior and therapeutic outcomes.
- The study emphasizes the underexplored role of keratinocytes in the melanoma microenvironment and their contribution to tumor growth and drug resistance.
- Understanding cell–cell interactions within the melanoma niche may provide new molecular targets for personalized melanoma therapy.

</div>

Introduction

Melanoma originates from pigment-producing cells, melanocytes, and is characterized by the highest mortality rate among skin cancers. One of the most significant risk factors for melanoma is prolonged exposure to ultraviolet (UV) radiation. In healthy skin, melanocytes interact with keratinocytes and other neighboring cells to protect DNA from UV-induced damage, primarily through melanin-dependent mechanisms.[1]

Mutations in genes encoding proteins associated with the mitogen-activated protein kinase (MAPK) pathway, such as serine/threonine-protein kinase B-Raf (BRAF) and NRAS, account for approx. 70% of genetic aberrations induced by UV irradiation.[2] A mutation in the BRAF gene (BRAF V600E) occurs in about 50% of melanoma patients and results in a constitutively active kinase.[3,4] Several targeted therapies against melanoma-specific molecular markers, including mutated BRAF, are currently used in clinical practice. Nevertheless, resistance to these drugs often develops rapidly in treated patients.[5,6] For all patients with invasive cutaneous melanoma, surgical excision of the primary tumor with 1–2 cm margins remains the standard of oncologic management. Sentinel lymph node biopsy (SLNB) is recommended for patients with T1b or more advanced melanoma (tumor thickness >0.8 mm or any tumor with ulceration).[7] In patients with sentinel lymph node micrometastasis, complete lymph node dissection (CLND) is no longer performed, based on the findings of the DeCOG and MSLT-II clinical trials.[8] Instead of extensive surgical intervention, systemic adjuvant therapy has proven more effective in improving disease-free survival (DFS) and overall survival (OS). High-risk stage IIB/C melanoma (T3b–T4b tumors with negative SLNB) is currently also an indication for 1 year of adjuvant immunotherapy with pembrolizumab or nivolumab (anti–PD-1 agents).[9,10] In patients with clinically detected metastatic lymph nodes or skin in-transit metastases (resectable stage III), the standard of care includes therapeutic lymph node dissection (TLND) or resection of in-transit tumors, followed by 1 year of adjuvant systemic treatment with either targeted therapy (dabrafenib and trametinib – BRAF/MEK inhibitors) or immunotherapy (pembrolizumab or nivolumab – anti–PD-1). New systemic adjuvant therapies improve OS and relapse-free survival (RFS) by approx. 20%.[11–13]

Before the advent of immunotherapies and targeted therapies, chemotherapy was the only treatment option for patients with stage IV melanoma (disseminated disease) and was associated with very poor outcomes. Today, it is used only in patients who are resistant to modern systemic treatments.[14] For patients with unresectable stage III melanoma (metastatic lymph nodes or skin metastases) or stage IV disease, several systemic treatment options are available, similar to those used in the adjuvant setting. In BRAF-mutated patients, either immunotherapy or targeted therapy may be employed, whereas in BRAF wild-type patients, immunotherapy remains the standard of care. The combination of nivolumab and ipilimumab has demonstrated superiority over either agent used as monotherapy, providing a durable survival benefit in terms of progression-free survival (PFS) and melanoma-specific survival (MSS).[15,16] Radiotherapy may also be effective for melanoma patients with bone or brain metastases, although its use is limited to palliative settings.[17,18]

Among the factors influencing the effectiveness of anticancer therapy is the tumor microenvironment (TME). Solid tumors are composed not only of malignant cells but also of various nonmalignant components within the tumor niche, including keratinocytes, cancer-associated fibroblasts (CAFs), immune cells, and adipocytes.[19,20] Additional elements, such as the composition of the extracellular matrix (ECM) and physical factors like hypoxia, must also be considered.[21–23] The TME exerts diverse effects on melanoma progression and the development of therapy resistance. Initially, the TME may act as a physical barrier that limits drug delivery to cancer cells.[24] In addition, stromal cells within the melanoma TME can promote tumor growth and enhance its invasive and angiogenic potential through paracrine signaling. These cells secrete growth factors, cytokines and chemokines that influence not only neighboring cells within the niche but also distant sites in the body.[25] Moreover, they produce matrix metalloproteinases (MMPs), which degrade ECM

components, thereby creating pathways that facilitate cancer cell invasion through surrounding tissues.[26] Cells within the TME can also secrete high-energy metabolites that are subsequently utilized by melanoma cells.[27] Finally, immune cells, while initially contributing to the elimination of malignantly transformed cells, begin, during tumor progression, to facilitate immune evasion by melanoma cells. This occurs through various mechanisms, including the secretion of proinflammatory factors, expression of inhibitory receptors and induction of pro-tumor immune cell phenotypes.[20]

In our research, we focused on the effects of cells present in the melanoma microenvironment on cancer progression and the development of therapy resistance. In particular, we examined stromal cells accompanying melanoma cells in the tumor: CAFs, CAKs and CAAs. Special attention was given to keratinocytes, as their role in the melanoma microenvironment remains the least understood.

Keratinocytes play a protective role toward melanocytes in healthy skin; however, their interactions with cancer cells following melanomagenesis remain poorly understood. Under physiological conditions, keratinocytes regulate melanocyte proliferation through paracrine signaling and direct interactions mediated by E-cadherin-dependent cell–cell adhesion.[19,28] During melanoma development, E-cadherin expression decreases, while N-cadherin expression increases, leading to the loss of keratinocyte-mediated control over melanocytes. As a result, melanocytes begin to interact with N-cadherin-expressing cells such as fibroblasts.[16]

The cadherin switch is regulated by transcription factors involved in the epithelial–mesenchymal transition (EMT), such as Snail, Twist and Slug, and may contribute to melanoma tumorigenesis.[29] Moreover, Hsu et al. demonstrated that restoring E-cadherin expression in melanoma cells reestablishes their connection with keratinocytes, thereby reducing melanoma cell growth.[30] In addition, keratinocytes exposed to UV radiation activate DNA repair pathways in melanocytes through the secretion of endothelin-1 (End-1) and α-melanocortin, thereby inhibiting melanocyte transformation into melanoma.[31] Conversely, some studies suggest a pro-tumorigenic influence of keratinocytes on melanoma cells. It has been demonstrated that endothelin-1 secreted by keratinocytes activates caspase-8, which transiently binds to the E-cadherin/catenin complex in melanoma cells, leading to reduced E-cadherin expression and enhanced cancer cell invasion.[32] Furthermore, extracellular End-1 has been shown to stimulate extracellular signal-regulated kinase (ERK) activation in melanoma cells treated with BRAF inhibitors. Moreover, End-1 expression is influenced by the level of melanocyte-inducing transcription factor (MITF). Overexpression of MITF enhances End-1 production, whereas its depletion is associated with End-1 downregulation. Furthermore, inhibition of endothelin receptor B increases the sensitivity of BRAF inhibitor-resistant melanoma

cells to treatment.[19,33] Additionally, under the influence of fibroblast-derived keratinocyte growth factor (KGF), keratinocytes secrete the c-KIT ligand, stem cell factor (SCF), which subsequently activates the protein kinase B (AKT) and MAPK pathways, regulating cancer cell invasion and proliferation.[34] Reports on the effects of melanoma on keratinocytes are scarce. One such study demonstrated alterations in the levels of intermediate filament proteins – cytokeratins – associated with the differentiation status of keratinocytes.[35,36] Cytokeratin 10 (CK10) is expressed in suprabasal keratinocytes undergoing cornification and desquamation, whereas cytokeratin 14 (CK14) is highly expressed in rapidly proliferating basal keratinocytes. Kodet et al. demonstrated that melanoma cells alter cytokeratin expression profiles in keratinocytes, leading to upregulation of CK14 and downregulation of CK10.[37] Our findings indicate that keratinocytes activated through indirect co-culture with melanoma cells or incubation with melanoma-conditioned medium exhibit characteristics of less differentiated cells, including decreased CK10 expression, and show a preference for interacting with cancer cells rather than with other keratinocytes, likely due to reduced E-cadherin levels. Activated keratinocytes secrete a wide range of proteases, several of which, such as matrix metalloproteinase 3 (MMP3), were first identified by our group as components of the activated keratinocyte secretome. These keratinocytes display high proteolytic activity, characterized by increased activity of MMP9 and MMP14 and decreased expression of tissue inhibitors of metalloproteinases (TIMPs). They also exhibit elevated ERK activity and increased levels of MMP expression regulators, including runt-related transcription factor 2 (RUNX2) and galectin-3. Furthermore, cancer-associated keratinocytes (CAKs) demonstrate enhanced migratory and invasive abilities following co-culture with melanoma cells in Transwell assays.[37]

Fibroblasts represent the most abundant cell population within the melanoma niche, comprising up to 80% of the tumor mass.[38] In our study, we utilized 4 melanoma cell lines differing in invasiveness: 2 derived from primary tumors (WM1341D and A375) and 2 from lymph node metastases (WM9 and Hs294T). Importantly, when comparing the effects of these melanoma cells on fibroblast characteristics, we considered both their origin and invasive potential. An earlier study by Makowiecka et al.[39] demonstrated that A375, WM9 and Hs294T cells exhibit higher rates of migration, invasion and proteolytic activity, as well as greater invadopodia formation, compared with WM1341D cells. Therefore, we classified the WM1341D cell line as less aggressive, while A375, WM9 and Hs294T were considered highly aggressive melanoma cell lines. We observed that fibroblasts co-cultured with melanoma cells exhibited increased motility, enhanced proteolytic activity and elevated secretion of several cytokines, lactate and angiogenesis-related proteins. The observed alterations in CAF biology were primarily induced by the highly

aggressive melanoma cell lines (A375, WM9 and Hs294T), rather than by the less aggressive WM1341D line.[40] These CAF-associated features can promote melanoma invasion and contribute to angiogenesis, inflammation and acidification of the TME. Adipocytes, another cellular component of the melanoma niche, are located in the deepest layer of the skin. The interactions between adipocytes and melanoma cells remain poorly understood, and the influence of obesity on melanoma progression is still controversial.[41] Cancer-associated adipocytes (CAAs) were obtained by differentiating 3T3-L1 preadipocytes into mature adipocytes according to the protocol described by Zebisch et al.[42] Subsequently, mature adipocytes were co-cultured with melanoma cells using Transwell inserts. The transformation of adipocytes into CAAs was evaluated based on the expression of markers characteristic of differentiated adipocytes, which are typically reduced in CAAs. We also observed that melanoma-associated adipocytes exhibited decreased levels of adipogenesis markers and a reduced number of lipid droplets. Moreover, we observed that adipocytes exposed to melanoma cells undergo dedifferentiation into fibroblast-like cells. Cancer-associated adipocytes also exhibited significantly increased lactate release and upregulated expression of transporters for lactate, H^+ ions and glucose, likely reflecting substantial metabolic reprogramming within the TME. The secreted lactate may serve as an energy source for melanoma cells, thereby promoting their proliferation. Concurrently, CAAs showed enhanced activation of specific signaling pathways, including extracellular signal-regulated kinase (ERK) and signal transducer and activator of transcription 3 (STAT3), along with decreased secretion of angiogenesis-related factors.[43]

Conclusions

In the past, cancer cells were considered the sole target of anticancer therapy. Today, it is well recognized that cells within the tumor niche also play a crucial role in cancer dissemination. These cells influence cancer behavior both through paracrine signaling and direct cell–cell interactions. Notably, all of the described cell types contribute to the development of drug resistance and may therefore represent potential therapeutic targets in melanoma treatment.

Use of AI and AI-assisted technologies

Not applicable.

ORCID iDs

Rafał Matkowski   https://orcid.org/0000-0002-1705-5097
Aleksandra Simiczyjew   https://orcid.org/0000-0002-6060-2375
Marcin Ziętek   https://orcid.org/0000-0002-7890-3483
Dorota Nowak   https://orcid.org/0000-0002-6426-1686

References

1. Williams PF, Olsen CM, Hayward NK, Whiteman DC. Melanocortin 1 receptor and risk of cutaneous melanoma: A meta-analysis and estimates of population burden. *Int J Cancer*. 2011;129(7):1730–1740. doi:10.1002/ijc.25804

2. Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. *Cancer Biol Ther*. 2019;20(11):1366–1379. doi:10.1080/15384047.2019.1640032

3. Rebecca VW, Sondak VK, Smalley KSM. A brief history of melanoma: From mummies to mutations. *Melanoma Res*. 2012;22(2):114–122. doi:10.1097/CMR.0b013e328351fa4d

4. Schreck KC, Grossman SA, Pratilas CA. BRAF nutations and the utility of RAF and MEK inhibitors in primary brain tumors. *Cancers (Basel)*. 2019;11(9):1262. doi:10.3390/cancers11091262

5. Luebker SA, Koepsell SA. Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies. *Front Oncol*. 2019;9:268. doi:10.3389/fonc.2019.00268

6. Kim A, Cohen MS. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. *Exp Opin Drug Discov*. 2016;11(9):907–916. doi:10.1080/17460441.2016.1201057

7. Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2. Treatment: Update 2019. *Eur J Cancer*. 2020;126:159–177. doi:10.1016/j.ejca.2019.11.015

8. Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2018;36(4):399–413. doi:10.1200/JCO.2017.75.7724

9. Kirkwood JM, Del Vecchio M, Weber J, et al. Adjuvant nivolumab in resected stage IIB/C melanoma: Primary results from the randomized, phase 3 CheckMate 76K trial. *Nat Med*. 2023;29(11):2835–2843. doi:10.1038/s41591-023-02583-2

10. Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): A randomised, double-blind, phase 3 trial. *Lancet*. 2022;399(10336):1718–1729. doi:10.1016/S0140-6736(22)00562-1

11. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III *BRAF*-mutated melanoma. *N Engl J Med*. 2017;377(19):1813–1823. doi:10.1056/NEJMoa1708539

12. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. *N Engl J Med*. 2018;378(19):1789–1801. doi:10.1056/NEJMoa1802357

13. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. *N Engl J Med*. 2017;377(19):1824–1835. doi:10.1056/NEJMoa1709030

14. Goldinger SM, Buder-Bakhaya K, Lo SN, et al. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: A retrospective multicentre analysis. *Eur J Cancer*. 2022;162:22–33. doi:10.1016/j.ejca.2021.11.022

15. Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2018;19(11):1480–1492. doi:10.1016/S1470-2045(18)30700-9

16. Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med*. 2025;392(1):11–22. doi:10.1056/NEJMoa2407417

17. Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: Brain metastases, bone metastases, and spinal cord compression. *Int J Radiat Oncol Biol Phys*. 1988;15(4):859–864. doi:10.1016/0360-3016(88)90118-6

18. Garsa A, Jang JK, Baxi S, et al. Radiation therapy for brain metastases: A systematic review. *Pract Radiat Oncol*. 2021;11(5):354–365. doi:10.1016/j.prro.2021.04.002

19. Mazurkiewicz J, Simiczyjew A, Dratkiewicz E, Ziętek M, Matkowski R, Nowak D. Stromal cells present in the melanoma niche affect tumor invasiveness and its resistance to therapy. *Int J Mol Sci*. 2021;22(2):529. doi:10.3390/ijms22020529

20. Simiczyjew A, Dratkiewicz E, Mazurkiewicz J, Ziętek M, Matkowski R, Nowak D. The influence of tumor microenvironment on immune escape of melanoma. *Int J Mol Sci*. 2020;21(21):8359. doi:10.3390/ijms21218359

21. Dratkiewicz E, Simiczyjew A, Mazurkiewicz J, Ziętek M, Matkowski R, Nowak D. Hypoxia and extracellular acidification as drivers of melanoma progression and drug resistance. *Cells*. 2021;10(4):862. doi:10.3390/cells10040862

22. Ruiter D, Bogenrieder T, Elder D, Herlyn M. Melanoma-stroma interactions: Structural and functional aspects. *Lancet Oncol*. 2002;3(1):35–43. doi:10.1016/s1470-2045(01)00620-9

23. Gurzu S, Beleaua MA, Jung I. The role of tumor microenvironment in development and progression of malignant melanomas: A systematic review. *Rom J Morphol Embryol*. 2018;59(1):23–28. PMID:29940608.

24. Sriraman SK, Aryasomayajula B, Torchilin VP. Barriers to drug delivery in solid tumors. *Tissue Barriers*. 2014;2(3):e29528. doi:10.4161/tisb.29528

25. Labrousse AL, Ntayi C, Hornebeck W, Bernard P. Stromal reaction in cutaneous melanoma. *Crit Rev Oncol Hematol*. 2004;49(3):269–275. doi:10.1016/j.critrevonc.2003.10.007

26. Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H. Cancer-associated fibroblasts: Their characteristics and their roles in tumor growth. *Cancers (Basel)*. 2015;7(4):2443–2458. doi:10.3390/cancers7040902

27. Shu SL, Yang Y, Allen CL, et al. Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. *Sci Rep*. 2018;8(1):12905. doi:10.1038/s41598-018-31323-7

28. Wang JX, Fukunaga-Kalabis M, Herlyn M. Crosstalk in skin: Melanocytes, keratinocytes, stem cells, and melanoma. *J Cell Commun Signal*. 2016;10(3):191–196. doi:10.1007/s12079-016-0349-3

29. Kuphal S, Bosserhoff AK. E-cadherin cell–cell communication in melanogenesis and during development of malignant melanoma. *Arch Biochem Biophys*. 2012;524(1):43–47. doi:10.1016/j.abb.2011.10.020

30. Hsu MY, Meier FE, Nesbit M, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. *Am J Pathol*. 2000;156(5):1515–1525. doi:10.1016/S0002-9440(10)65023-7

31. Swope VB, Starner RJ, Rauck C, Abdel-Malek ZA. Endothelin-1 and α-melanocortin have redundant effects on global genome repair in UV-irradiated human melanocytes despite distinct signaling pathways. *Pigment Cell Melanoma Res*. 2020;33(2):293–304. doi:10.1111/pcmr.12823

32. Jamal S, Schneider RJ. UV-induction of keratinocyte endothelin-1 down-regulates E-cadherin in melanocytes and melanoma cells. *J Clin Invest*. 2002;110(4):443–452. doi:10.1172/JCI0213729

33. Smith MP, Rowling EJ, Miskolczi Z, et al. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. *EMBO Mol Med*. 2017;9(8):1011–1029. doi:10.15252/emmm.201607156

34. Belleudi F, Cardinali G, Kovacs D, Picardo M, Torrisi MR. KGF promotes paracrine activation of the SCF/c-KIT axis from human keratinocytes to melanoma cells. *Transl Oncol*. 2010;3(2):80–90. doi:10.1593/tlo.09196

35. Alam H, Sehgal L, Kundu ST, Dalal SN, Vaidya MM. Novel function of keratins 5 and 14 in proliferation and differentiation of stratified epithelial cells. *Mol Biol Cell*. 2011;22(21):4068–4078. doi:10.1091/mbc.e10-08-0703

36. Kodet O, Lacina L, Krejčí E, et al. Melanoma cells influence the differentiation pattern of human epidermal keratinocytes. *Mol Cancer*. 2015;14(1):1. doi:10.1186/1476-4598-14-1

37. Mazurkiewicz J, Simiczyjew A, Dratkiewicz E, et al. Melanoma stimulates the proteolytic activity of HaCaT keratinocytes. *Cell Commun Signal*. 2022;20(1):146. doi:10.1186/s12964-022-00961-w

38. Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: Orchestrating the composition of malignancy. *Genes Dev*. 2016;30(9):1002–1019. doi:10.1101/gad.279737.116

39. Makowiecka A, Simiczyjew A, Nowak D, Mazur AJ. Varying effects of EGF, HGF and TGFβ on formation of invadopodia and invasiveness of melanoma cell lines of different origin. *Eur J Histochem*. 2016;60(4):2728. doi:10.4081/ejh.2016.2728

40. Mazurkiewicz J, Simiczyjew A, Dratkiewicz E, et al. Melanoma cells with diverse invasive potential differentially induce the activation of normal human fibroblasts. *Cell Commun Signal*. 2022;20(1):63. doi:10.1186/s12964-022-00871-x

41. Smith LK, Arabi S, Lelliott EJ, McArthur GA, Sheppard KE. Obesity and the impact on cutaneous melanoma: Friend or foe? *Cancers (Basel)*. 2020;12(6):1583. doi:10.3390/cancers12061583

42. Zebisch K, Voigt V, Wabitsch M, Brandsch M. Protocol for effective differentiation of 3T3-L1 cells to adipocytes. *Anal Biochem*. 2012;425(1):88–90. doi:10.1016/j.ab.2012.03.005

43. Simiczyjew A, Wądzyńska J, Pietraszek-Gremplewicz K, et al. Melanoma cells induce dedifferentiation and metabolic changes in adipocytes present in the tumor niche. *Cell Mol Biol Lett*. 2023;28(1):58. doi:10.1186/s11658-023-00476-3